This aspect is exacerbated in some tumours such as muscular-invasive bladder cancer and in prostate cancers, where not only ARF levels appear increased, but the protein is also involved in the epithelial-to-mesenchymal transition and chemoresistance [10,11,12]. Here, CDKN2A is linked to neoplasm.